COVID-19
Conditions
Brief summary
Many laboratory biomarkers were used for diagnosis of COVID-19 infection; however, their accuracy to assess the severity and prognosis are still to be evaluated. Aim: to correlate between the serum Ferritin and D-dimer levels and the severity of COVID-19 infection and its outcome (mortality, days of hospital stay, ICU admission or mechanical ventilation). A retrospective study conducted by retrieving patients' data who were admitted to Ain Shams University Specialized Hospital - Obour branch and diagnosed with COVID-19 infection in the period from 1st of April 2020 to 31st of July 2020.
Detailed description
Aim of the study: to correlate between the serum level of Ferritin and D-dimer and the severity of COVID-19 infection as well as its outcome Material and methods: It is a retrospective study conducted by retrieving data of patients diagnosed with COVID-19 infection PCR positive for SARS-CoV2 who were admitted to Ain Shams University Specialized Hospital - Obour branch in the period from 1st of April 2020 to 31st of July 2020. The following data were collected from the studied patients' files: • Demographic characteristics (age, sex, marital status, smoking status, co-morbidities), Source of infection, degree of severity of COVID-19 infection according to WHO Clinical management of COVID-19: interim guidance. The investigations done include: Laboratory investigations: including; (Complete blood picture, Iron profile, Liver function tests, D-dimer (Using: using Biomerieux-VIDAS, Serial number IVD3002806, Manufactured in 2008, Marcy l'Étoile, France Reference range: 0-500 ng/ml) and Serum Ferritin (using ABBOT-Architect 1000, Serial number I1SR62514, Manufactured in 2010, Chicago, Illinois, United States.Reference range: 13-150 ng/ml (Figure number 2) Radiological investigations: By High resolution CT chest (Using: Toshiba 16-slice CT scanner, model number: activion 16, Manufactured in 2010, Japan) severity scoring was done using 25-point CT severity score Li et al, 2020. Score of 7 or less was considered as mild affection, 8-17 was considered as moderate affection and 18 or more was considered as severe affection Saeed et al 2021 Inclusion Criteria: Hospitalized isolated patients in Ain Shams University Specialized Hospital - Obour branch with COVID-19 infection confirmed by Polymerase chain reaction (PCR) positive for SARS-CoV2. Exclusion Criteria: * COVID-19 patients with other conditions altering the serum Ferritin level; For example; iron deficiency anemia, defective intestinal absorption, internal bleeding, rheumatoid arthritis, hyperthyroidism, leukemia, Hodgkin's lymphoma, frequent blood transfusions and advanced liver disease Child-Pugh score C. * COVID-19 patients with other conditions altering the serum D-dimer level; For example; known pulmonary embolism, known Deep Venous Thrombosis DVT, pregnancy, heart failure, trauma, active malignancy, septicemia, disseminated Intra-vascular Coagulopathy DIC. * The patients with any missing studied data were also excluded. Data was correlated with the clinical spectrum of severity and the patient outcome regarding: death or recovery, days of hospital stay, need for ICU admission and need for mechanical ventilation.
Interventions
Blood venous sample
Sponsors
Study design
Eligibility
Inclusion criteria
* Hospitalized isolated patients in Ain Shams University Specialized Hospital - Obour with COVID-19 infection confirmed by Polymerase chain reaction (PCR) positive for SARS-CoV2.
Exclusion criteria
* • COVID-19 patients with other conditions altering the serum Ferritin level; For example; iron deficiency anemia, defective intestinal absorption, internal bleeding, rheumatoid arthritis, hyperthyroidism, leukemia, Hodgkin's lymphoma, frequent blood transfusions and advanced liver disease Child-Pugh score C. * COVID-19 patients with other conditions altering the serum D-dimer level; For example; known pulmonary embolism, known Deep Venous Thrombosis DVT, pregnancy, heart failure, trauma, active malignancy, septicemia, disseminated Intra-vascular Coagulopathy DIC. * The patients with any missing studied data were also excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality | Till study completion, an average of 4 months |
| Need for Mechanical ventilation | Till study completion, an average of 4 months |
Countries
Egypt